Clinical trial • Phase I • Neurology
Clinical trial in Parkinson's disease
Phase I trial for Parkinson's disease. 200 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Parkinson's disease
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 27-11-2023
- First CTIS Authorization Date
- 25-01-2024
Trial design
Phase I trial across 2 sites in Netherlands.
- Target Sample Size
- 200
Eligibility
Recruits 200 Vulnerable population not selected; no specific consent/assent handling described in the record..
- Vulnerable Population
- Vulnerable population not selected; no specific consent/assent handling described in the record.
Recruitment
- Planned Sample Size
- 200
- Recruitment Window Months
- 31
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 200
Netherlands
- Earliest CTIS Part Ii Submission Date
- 22-01-2024
- Latest Decision Or Authorization Date
- 24-09-2025
- Processing Time Days
- 611
- Number Of Sites
- 2
- Number Of Participants
- 200
Sites
- Site Name
- Pharmaceutical Research Associates Group B.V.
- Department Name
- General
- Contact Person Name
- Renger Tiessen
- Contact Person Email
- renger.tiessen@iconplc.com
- Site Name
- Centre for Human Drug Research
- Department Name
- Neurology
- Contact Person Name
- Philip Kremer
- Contact Person Email
- clintrials@chdr.nl
Sponsor
Primary sponsor
- Full Name
- Vanqua Bio Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Contract research organisations
- Name
- Pharmaceutical Research Associates Group B.V.
Related trials
Other published trials that may interest you.